Nepidermin

Summary

Nepidermin is a recombinant human epidermal growth factor (rhEGF) analog developed primarily for topical wound-healing applications, including chronic wounds, diabetic ulcers, and burns. It stimulates epithelial cell proliferation and migration via EGFR activation. It has been investigated in clinical trials and has limited regional approvals or compassionate-use programs in some countries.

Mechanism of Action

Binds to epidermal growth factor receptors (EGFR/ErbB1) on cell surfaces, activating receptor tyrosine kinase signaling cascades (RAS/MAPK, PI3K/AKT) that promote cell proliferation, migration, and survival, thereby accelerating wound healing and epithelial tissue regeneration.

Routes of Administration

Goals & Uses

• Diabetic foot ulcer healingWound HealingModerate
• Post-surgical wound recoveryTissue RepairLow
• Burn wound healingWound HealingModerate
• Chronic wound closureWound HealingModerate
• Corneal epithelial repairOphthalmologyLow

Contraindications

• Known malignancy at or near application siteOncologyHigh
• Active wound infection (uncontrolled)Infectious DiseaseModerate
• Hypersensitivity to EGF or excipientsAllergy/immunologyHigh

Adverse Effects

• Erythema at application siteDermatologicCommon
• Hypersensitivity/allergic reactionImmunologicalRare
• Granuloma formationLocal ReactionRare
• Local injection site pain/burningLocal ReactionCommon
• Local edemaLocal ReactionUncommon

Drug Interactions

• EGFR inhibitors (e.g., erlotinib, cetuximab)High
• Corticosteroids (topical/systemic)Moderate

Population Constraints

• Patients with active malignanciesOncologyAbsolute
• Pediatric patientsAgeRelative
• Immunocompromised patientsImmunologicRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalNot approved by EMA; remains under research in European clinical trials.
• United StatesInvestigationalNo FDA approval for nepidermin specifically; investigational status under various IND applications for wound healing.
• United KingdomUnknownNo known MHRA approval; status mirrors EU regulatory landscape post-Brexit.

Not approved by FDA or EMA as a standalone therapeutic. Various rhEGF formulations have received approvals in Cuba (Heberprot-P, intralesional EGF for diabetic foot ulcers) and some Asian markets. Nepidermin specifically remains largely investigational in major Western regulatory frameworks.

Evidence & Sources

No sources recorded yet.